| Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with … P Dombernowsky, I Smith, G Falkson, R Leonard, L Panasci, J Bellmunt, ... Journal of clinical oncology 16 (2), 453-461, 1998 | 818 | 1998 |
| Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial JFR Robertson, IM Bondarenko, E Trishkina, M Dvorkin, L Panasci, ... The Lancet 388 (10063), 2997-3005, 2016 | 605 | 2016 |
| External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative … TJ Whelan, JA Julian, TS Berrang, DH Kim, I Germain, AM Nichol, M Akra, ... The Lancet 394 (10215), 2165-2172, 2019 | 337 | 2019 |
| Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase C Algire, L Amrein, M Zakikhani, L Panasci, M Pollak Endocrine-related cancer 17 (2), 351, 2010 | 296 | 2010 |
| Systemic cancer therapy: achievements and challenges that lie ahead MO Palumbo, P Kavan, WH Miller Jr, L Panasci, S Assouline, N Johnson, ... Frontiers in pharmacology 4, 57, 2013 | 287 | 2013 |
| Epstein‐Barr virus related lymphoepithelioma‐like carcinoma of lung LR Bégin, J Eskandari, J Joncas, L Panasci Journal of surgical oncology 36 (4), 280-283, 1987 | 280 | 1987 |
| Small molecules, inhibitors of DNA-PK, targeting DNA repair, and beyond D Davidson, L Amrein, L Panasci, R Aloyz Frontiers in pharmacology 4, 5, 2013 | 182 | 2013 |
| Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial S Chia, M Clemons, LA Martin, A Rodgers, K Gelmon, GR Pond, ... Journal of clinical oncology 24 (18), 2773-2778, 2006 | 167 | 2006 |
| Chemotherapy for advanced pancreatic cancer. A comparison of 5‐fluorouracil, adriamycin, and mitomycin (FAM) with 5‐fluorouracil, streptozotocin, and mitomycin (FSM) MW Oster, R Gray, L Panasci, MC Perry Cancer 57 (1), 29-33, 1986 | 163 | 1986 |
| Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair L Panasci, JP Paiement, G Christodoulopoulos, A Belenkov, A Malapetsa, ... Clinical Cancer Research 7 (3), 454-461, 2001 | 139 | 2001 |
| DNA-dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards C Muller, G Christodoulopoulos, B Salles, L Panasci Blood, The Journal of the American Society of Hematology 92 (7), 2213-2219, 1998 | 132 | 1998 |
| Are frailty markers useful for predicting treatment toxicity and mortality in older newly diagnosed cancer patients? Results from a prospective pilot study MTE Puts, J Monette, V Girre, C Pepe, M Monette, S Assouline, L Panasci, ... Critical reviews in oncology/hematology 78 (2), 138-149, 2011 | 128 | 2011 |
| Xenografts of human hepatocellular carcinoma: a useful model for testing drugs H Huynh, KC Soo, PKH Chow, L Panasci, E Tran Clinical cancer research 12 (14), 4306-4314, 2006 | 125 | 2006 |
| Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group … D Perrault, EA Eisenhauer, KI Pritchard, L Panasci, B Norris, ... Journal of Clinical Oncology 14 (10), 2709-2712, 1996 | 125 | 1996 |
| Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD R Aloyz, ZY Xu, V Bello, J Bergeron, FY Han, Y Yan, A Malapetsa, ... Cancer research 62 (19), 5457-5462, 2002 | 123 | 2002 |
| Increased DNA synthesis and repair-enzyme expression in lymphocytes from patients with chronic lymphocytic leukemia resistant to nitrogen mustards R Geleziunas, A McQuillan, A Malapetsa, M Hutchinson, D Kopriva, ... JNCI: Journal of the National Cancer Institute 83 (8), 557-564, 1991 | 111 | 1991 |
| A structure-activity analysis of chemical and biological parameters of chloroethylnitrosoureas in mice LC Panasci, D Green, R Nagourney, P Fox, PS Schein Cancer Research 37 (8_Part_1), 2615-2618, 1977 | 111 | 1977 |
| Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE) T Bachelot, E Ciruelos, A Schneeweiss, F Puglisi, T Peretz-Yablonski, ... Annals of Oncology 30 (5), 766-773, 2019 | 107 | 2019 |
| Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) KI Pritchard, J Rolski, Z Papai, L Mauriac, F Cardoso, J Chang, L Panasci, ... Breast cancer research and treatment 123, 453-461, 2010 | 106 | 2010 |
| An antisense oligonucleotide targeted to human Ku86 messenger RNA sensitizes M059K malignant glioma cells to ionizing radiation, bleomycin, and etoposide but not DNA cross … AI Belenkov, JP Paiement, LC Panasci, BP Monia, TYK Chow Cancer research 62 (20), 5888-5896, 2002 | 101 | 2002 |
